Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9)

Zoltán Szekanecz; Maya H. Buch; Christina Charles-Schoeman; James Galloway; George A. Karpouzas; Lars Erik Kristensen; Steven R. Ytterberg; Attila Hamar; Roy Fleischmann

doi:10.1038/s41584-024-01085-w

Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9)

Zoltán Szekanecz, Maya H. Buch, Christina Charles-Schoeman, James Galloway, George A. Karpouzas, Lars Erik Kristensen, Steven R. Ytterberg, Attila Hamar, Roy Fleischmann

Rheumatology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Reviews Rheumatologyhttps://doi.org/10.1038/s41584-023-01062-9, published online 12 January 2024. In the version of the article initially published, in the Abstract, the sentence now reading “tofacitinib was statistically not non-inferior to TNF inhibitors” read “tofacitinib was statistically inferior to TNF inhibitors”.

Original language	English (US)
Pages (from-to)	196
Number of pages	1
Journal	Nature Reviews Rheumatology
Volume	20
Issue number	3
DOIs	https://doi.org/10.1038/s41584-024-01085-w
State	Published - Mar 2024

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1038/s41584-024-01085-w

Cite this

Szekanecz, Z., Buch, M. H., Charles-Schoeman, C., Galloway, J., Karpouzas, G. A., Kristensen, L. E., Ytterberg, S. R., Hamar, A., & Fleischmann, R. (2024). Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9). Nature Reviews Rheumatology, 20(3), 196. https://doi.org/10.1038/s41584-024-01085-w

Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9). / Szekanecz, Zoltán; Buch, Maya H.; Charles-Schoeman, Christina et al.
In: Nature Reviews Rheumatology, Vol. 20, No. 3, 03.2024, p. 196.

Research output: Contribution to journal › Comment/debate › peer-review

Szekanecz, Z, Buch, MH, Charles-Schoeman, C, Galloway, J, Karpouzas, GA, Kristensen, LE, Ytterberg, SR, Hamar, A & Fleischmann, R 2024, 'Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9)', Nature Reviews Rheumatology, vol. 20, no. 3, pp. 196. https://doi.org/10.1038/s41584-024-01085-w

@article{a338aef1ddd5418394859b6d0b4e1887,

title = "Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9)",

abstract = "Correction to: Nature Reviews Rheumatologyhttps://doi.org/10.1038/s41584-023-01062-9, published online 12 January 2024. In the version of the article initially published, in the Abstract, the sentence now reading “tofacitinib was statistically not non-inferior to TNF inhibitors” read “tofacitinib was statistically inferior to TNF inhibitors”.",

author = "Zolt{\'a}n Szekanecz and Buch, {Maya H.} and Christina Charles-Schoeman and James Galloway and Karpouzas, {George A.} and Kristensen, {Lars Erik} and Ytterberg, {Steven R.} and Attila Hamar and Roy Fleischmann",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2024.",

year = "2024",

month = mar,

doi = "10.1038/s41584-024-01085-w",

language = "English (US)",

volume = "20",

pages = "196",

journal = "Nature Reviews Rheumatology",

issn = "1759-4790",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Correction to

T2 - Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9)

AU - Szekanecz, Zoltán

AU - Buch, Maya H.

AU - Charles-Schoeman, Christina

AU - Galloway, James

AU - Karpouzas, George A.

AU - Kristensen, Lars Erik

AU - Ytterberg, Steven R.

AU - Hamar, Attila

AU - Fleischmann, Roy

PY - 2024/3

Y1 - 2024/3

N2 - Correction to: Nature Reviews Rheumatologyhttps://doi.org/10.1038/s41584-023-01062-9, published online 12 January 2024. In the version of the article initially published, in the Abstract, the sentence now reading “tofacitinib was statistically not non-inferior to TNF inhibitors” read “tofacitinib was statistically inferior to TNF inhibitors”.

AB - Correction to: Nature Reviews Rheumatologyhttps://doi.org/10.1038/s41584-023-01062-9, published online 12 January 2024. In the version of the article initially published, in the Abstract, the sentence now reading “tofacitinib was statistically not non-inferior to TNF inhibitors” read “tofacitinib was statistically inferior to TNF inhibitors”.

UR - http://www.scopus.com/inward/record.url?scp=85183760283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85183760283&partnerID=8YFLogxK

U2 - 10.1038/s41584-024-01085-w

DO - 10.1038/s41584-024-01085-w

M3 - Comment/debate

C2 - 38302658

AN - SCOPUS:85183760283

SN - 1759-4790

VL - 20

SP - 196

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

IS - 3

ER -

Correction to: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Nature Reviews Rheumatology, (2024), 20, 2, (101-115), 10.1038/s41584-023-01062-9)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this